Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C

Table 3 Characteristics of the no-response group patients before IFN-α and ribavirin combination therapy

	Age(yr)	Sex	ALT	Transfusionhistory1	HCV RNAtiter2	ISDRtype3	No. of AminoAcid Mutationsof PePHD
B-1	53	M	185	×	5.25	1	0
B-2	48	M	320	×	6.11	1	0
B-3	44	F	125	○	4.88	1	0
B-4	49	F	175	×	5.72	1	0
B-5	54	M	151	○	6.21	1	0
B-6	58	F	190	×	5.14	1	0
B-7	62	F	212	×	6.35	1	0
B-8	64	M	252	○	7.11	1	0
B-9	45	M	145	×	6.82	1	0
B-10	49	M	138	×	4.95	1	0
B-11	42	F	120	○	5.54	1	0
B-12	55	M	95	×	6.25	1	0
B-13	53	M	142	×	6.73	1	0
B-14	55	F	185	×	6.76	1	0
B-15	57	M	258	×	4.85	1	0
B-16	53	F	175	○	6.33	2	0
B-17	49	M	241	×	5.81	2	0
B-18	44	M	183	×	6.32	2	0
B-19	59	F	167	×	5.89	2	0
B-20	54	M	171	○	6.14	2	0
B-21	52	F	217	×	6.23	2	0
B-22	55	M	222	×	5.88	2	0
B-23	63	F	235	×	6.32	2	0
B-24	47	F	161	×	6.47	2	0
B-25	51	M	96	○	5.31	2	0
B-26	54	F	80	×	5.85	2	0
B-27	55	F	192	○	6.42	3	0
B-28	58	M	234	×	5.93	3	0
B-29	48	M	341	×	4.98	3	0

ALT: Alanine aminotransferase; ISDR: Interferon sensitivity determining region.

¹○ indicates history of transfusion and × indicates no history of transfusion.

²The unit of HCV RNA titer before treatment (log copies/mL).

³ISDR type: 1 (wild type, no amino acid substitution), 2 (intermediate type, 1-3 amino acid substitutions), 3 (mutant type, ≥ 4 amino acid substitutions).